{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-001959","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.580366+00:00","generated_at":"2026-05-16T10:42:45.653258+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biofrontera reports record preliminary Q4 2025 revenue of $17.0-17.5M, up ~35-39% YoY","bullets":["Q4 2025 preliminary revenue $17.0-17.5M, highest quarterly revenue in history, YoY growth 35-39%.","Full year 2025 preliminary revenue $41.5-42.0M, YoY growth 11-13%.","CEO cites strong Ameluz sales execution and December pricing adjustment driving record quarter.","Recent transaction with Biofrontera AG expected to improve gross margin profile and strengthen finances.","Final Q4 and full year 2025 results to be reported in March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-001959","json":"https://secwatch.observer/filing/0001493152-26-001959.json","markdown":"https://secwatch.observer/filing/0001493152-26-001959.md","text":"https://secwatch.observer/filing/0001493152-26-001959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226001959/0001493152-26-001959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226001959/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:42:45.653258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}